Insider Selling: iRadimed (NASDAQ:IRMD) Director Sells $122,615.79 in Stock

iRadimed Corporation (NASDAQ:IRMD) Director Monty Allen sold 1,419 shares of iRadimed stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $86.41, for a total value of $122,615.79. Following the sale, the director directly owned 19,581 shares of the company’s stock, valued at $1,691,994.21. This trade represents a 6.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

iRadimed Stock Performance

Shares of NASDAQ:IRMD traded up $0.95 on Tuesday, hitting $84.40. 105,400 shares of the company’s stock were exchanged, compared to its average volume of 108,606. The firm’s 50-day moving average is $91.99 and its 200 day moving average is $93.49. The company has a market capitalization of $1.08 billion, a PE ratio of 47.15 and a beta of 0.89. iRadimed Corporation has a 1-year low of $67.84 and a 1-year high of $107.90.

iRadimed (NASDAQ:IRMD) last issued its earnings results on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.02. The business had revenue of $20.47 million for the quarter, compared to analyst estimates of $20.35 million. iRadimed had a return on equity of 23.45% and a net margin of 26.70%.iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. On average, analysts anticipate that iRadimed Corporation will post 1.98 EPS for the current fiscal year.

iRadimed Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 28th. Shareholders of record on Friday, August 14th were issued a dividend of $0.20 per share. The ex-dividend date of this dividend was Friday, August 14th. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. iRadimed’s dividend payout ratio (DPR) is presently 44.69%.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Quarry LP purchased a new stake in iRadimed in the third quarter valued at approximately $40,000. CWM LLC grew its position in shares of iRadimed by 19.5% during the fourth quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock worth $64,000 after acquiring an additional 107 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of iRadimed by 191.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 495 shares during the period. Global Retirement Partners LLC acquired a new position in shares of iRadimed in the 4th quarter valued at $85,000. Finally, Inspire Investing LLC purchased a new stake in iRadimed in the 1st quarter valued at $107,000. Institutional investors and hedge funds own 92.34% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on IRMD. Wall Street Zen cut shares of iRadimed from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings cut shares of iRadimed from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $120.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.